Amedeo Smart

Free Medical Literature Service

 

Amedeo

Hyperlipoproteinemias
  Free Subscription

Articles published in
Atherosclerosis
    April 2026
  1. WU HL, Chen JT, Cata JP, Cherng YG, et al
    Preoperative proprotein convertase subtilisin/kexin type 9 inhibitors versus statins and postoperative adverse events in hyperlipidemia: A nationwide, active-comparator cohort study.
    Atherosclerosis. 2026;417:120760.
    >> Share

  2. HUI Y, Tian G
    Methodological and clinical considerations in a Japanese cohort study of familial hypercholesterolemia and stroke.
    Atherosclerosis. 2026 Apr 23:120753. doi: 10.1016/j.atherosclerosis.2026.120753.
    >> Share

  3. PANG J, Gidding SS, Kelty E, Raal FJ, et al
    Liver transplantation in severe homozygous familial hypercholesterolaemia: a scoping review.
    Atherosclerosis. 2026;416:120730.
    >> Share

  4. MANSILLA-RODRIGUEZ ME, Sanchez-Ramos JL, Sanchez-Junco AR, Pang J, et al
    Risk factors for atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolemia: a systematic review and meta-analysis.
    Atherosclerosis. 2026;415:120650.
    >> Share

  5. LOU J, Chong KJ, Pek SLT, Bylstra Y, et al
    Cost-effectiveness of alternative cascade screening strategies for familial hypercholesterolemia with realistic cascade screening acceptance rates and use of novel treatment.
    Atherosclerosis. 2026;415:120416.
    >> Share

  6. KAFOL J, Sikonja J, Mlinaric M, Cugalj Kern B, et al
    LDLR and APOB pathogenic variants predict discordant TSH effect on LDL-C.
    Atherosclerosis. 2026;415:120672.
    >> Share

    March 2026
  7. SCHONCK WA, Hovingh GK, Blom DJ, Tromp T, et al
    Traditional cardiovascular risk factors and their association with atherosclerotic cardiovascular disease in homozygous familial hypercholesterolemia: A cross-sectional analysis from the HICC registry.
    Atherosclerosis. 2026;415:120717.
    >> Share

  8. JAYALEKSHMI VS, Basu B, Srijith S, Krishna G, et al
    Differential methylation of lipid metabolism and X-linked inheritance genes is associated with low placental efficiency, impaired fatty acid metabolism and oxidative stress in the placenta of hypercholesterolemic mothers.
    Atherosclerosis. 2026;415:120694.
    >> Share

  9. MANSFIELD BS, Bene-Alhasan Y, Ballantyne CM, Raal FJ, et al
    The evolving therapeutic landscape of PCSK9 inhibition.
    Atherosclerosis. 2026;414:120670.
    >> Share

    February 2026
  10. GALIMBERTI F, Capra ME, Olmastroni E, Braghiroli D, et al
    Real-world management of familial hypercholesterolemia in paediatric patients: a 3-year follow-up from the LIPIGEN registry.
    Atherosclerosis. 2026;415:120691.
    >> Share

  11. KLEVMOEN M, van Lennep JR, Bogsrud MP, Vesterbekkmo EK, et al
    Extensive pregnancy-related off-treatment time in women with familial hypercholesterolaemia.
    Atherosclerosis. 2026;415:120668.
    >> Share

  12. HATTORI Y, Noda K, Hori M, Nakaoku Y, et al
    Ischemic stroke and intracranial large-artery disease risk in familial hypercholesterolemia: A prospective Japanese study.
    Atherosclerosis. 2026;415:120674.
    >> Share

  13. HOLVEN KB, Raal FJ, Watts GF, Christensen JJ, et al
    Challenges in the care of woman with familial hypercholesterolaemia during the reproductive period - current evidence and practical guidance.
    Atherosclerosis. 2026;415:120679.
    >> Share

  14. RAAL FJ, Greber-Platzer S, Reeskamp LF, Iannuzzo G, et al
    Efficacy of evinacumab by genotype and low-density lipoprotein receptor function in patients with homozygous familial hypercholesterolaemia: A subanalysis from the ELIPSE open-label extension study.
    Atherosclerosis. 2026;414:120657.
    >> Share

  15. VAN DEN BOSCH SE, Kowsoleea FC, Corpeleijn WE, Huisman SA, et al
    Statin-associated symptoms and statin intolerance in children with familial hypercholesterolemia: Insights from 15 years of clinical practice.
    Atherosclerosis. 2026;414:120659.
    >> Share

  16. D'ERASMO L, Tramontano D, Di Costanzo A, Bini S, et al
    The hidden burden of kidney damage in chylomicronemia syndromes.
    Atherosclerosis. 2026;413:120621.
    >> Share

    January 2026
  17. MANCINI GBJ, Ryomoto A, Ruel I, Iatan I, et al
    Assessment of LDL receptor-dependent lipid lowering therapies in patients with homozygous familial hypercholesterolemia according to functional genotype.
    Atherosclerosis. 2026;414:120646.
    >> Share

  18. LI M, Tian D, Delafontaine P, Sukhanov S, et al
    Coronary atherosclerotic plaque composition and classification in hypercholesterolemic pigs.
    Atherosclerosis. 2026;413:120635.
    >> Share

    December 2025
  19. DALEY D, Ayoub A, Akyea RK, L'Esperance V, et al
    Systematic identification of familial hypercholesterolaemia: An updated systematic review and meta-analysis.
    Atherosclerosis. 2025;413:120625.
    >> Share

  20. ROSENSON RS, Brinton EA, Gaudet D, Raal FJ, et al
    Evinacumab in patients aged 5-17 years with homozygous familial hypercholesterolemia.
    Atherosclerosis. 2025;413:120627.
    >> Share

  21. SIKONJA J, Kobale K, Kafol J, Cugalj Kern B, et al
    Child-parent cascade screening for familial hypercholesterolemia in Slovenia: Insights from the pilot program.
    Atherosclerosis. 2025;411:120541.
    >> Share

  22. KAYIKCIOGLU M
    From universal screening to child-parent cascade: A family-centered approach to Familial hypercholesterolemia prevention.
    Atherosclerosis. 2025;411:120560.
    >> Share

    November 2025
  23. DA ROZA GV, Cermakova L, van Lennep JR, Holven KB, et al
    Lipid changes in females with familial hypercholesterolemia during the menopausal transition period.
    Atherosclerosis. 2025;413:120587.
    >> Share

  24. JOHN MANCINI GB, Ryomoto A, Ruel I, Iatan I, et al
    Imputation of untreated LDL-C in treated subjects with homozygous familial hypercholesterolaemia: An international collaboration.
    Atherosclerosis. 2025;412:120590.
    >> Share

  25. HARADA-SHIBA M, Santos RD
    Sex Differences and similarities in the Management of Familial Hypercholesterolemia during life course: learning from the younglings.
    Atherosclerosis. 2025;410:120518.
    >> Share

  26. KAFOL J, Becker M, Cugalj Kern B, Sikonja J, et al
    Sex differences in cholesterol levels among prepubertal children.
    Atherosclerosis. 2025;410:120484.
    >> Share

    October 2025
  27. MORAES T, Santos RD
    Dietary patterns and cardiovascular disease risk and its biomarkers in familial hypercholesterolemia: Looking beyond LDL-cholesterol.
    Atherosclerosis. 2025;409:120505.
    >> Share

  28. ARNOLD N, Gossling A, Weimann J, Bay B, et al
    Occurrence of coronary events in the absence of traditional risk factors: Understanding residual risk.
    Atherosclerosis. 2025;409:120475.
    >> Share

    September 2025
  29. KLINGEL R, Julius U, Bernhardt WM, Heigl F, et al
    Lipoprotein apheresis for lipoprotein(a)-associated progressive atherosclerotic cardiovascular disease: 12-years follow-up.
    Atherosclerosis. 2025;410:120508.
    >> Share

  30. YANG X, Alexander VJ, Xia S, Tsimikas S, et al
    Effect of olezarsen on lipoprotein-associated ApoC-III levels in patients with familial chylomicronemia syndrome.
    Atherosclerosis. 2025;408:120462.
    >> Share

  31. MIJNSTER RJM, Mulder JWCM, Galema-Boers AMH, Mattace-Raso F, et al
    Efficacy and safety of PCSK9 monoclonal antibodies in older patients: A real-world registry.
    Atherosclerosis. 2025;408:120229.
    >> Share

    July 2025
  32. CASTRO CABEZAS M, Klop B
    The "SMART" side of hypertriglyceridemia.
    Atherosclerosis. 2025 Jul 25:120467. doi: 10.1016/j.atherosclerosis.2025.120467.
    >> Share

  33. TOFT-NIELSEN F, Emanuelsson F, Nordestgaard BG, Benn M, et al
    Clinical familial hypercholesterolemia, heart healthy dietary adherence, and cardiovascular risk.
    Atherosclerosis. 2025 Jul 24:120463. doi: 10.1016/j.atherosclerosis.2025.120463.
    >> Share

  34. KAYIKCIOGLU M
    Making the invisible visible: Leveraging electronic health records to uncover familial hypercholesterolemia in primary care.
    Atherosclerosis. 2025 Jul 22:120454. doi: 10.1016/j.atherosclerosis.2025.120454.
    >> Share

  35. WANG H, Shen C, Yang Y, Li X, et al
    Pigment epithelium-derived factor prevents endothelial dysfunction in early stage of hyperlipidemia by regulating endothelial fatty acid transport.
    Atherosclerosis. 2025;408:120446.
    >> Share

  36. SVENDSEN K, Christensen JJ, Igland J, Krogh HW, et al
    Risk of adverse pregnancy outcomes and impact of statin use in pregnant women with familial hypercholesterolemia.
    Atherosclerosis. 2025;408:120442.
    >> Share

  37. AKYEA RK, Qureshi N
    Uncovering familial hypercholesterolaemia phenotype in the community: How primary care can transform early detection and management.
    Atherosclerosis. 2025 Jul 9:120427. doi: 10.1016/j.atherosclerosis.2025.120427.
    >> Share

  38. TADA H, Furukawa A, Kojima N, Usui S, et al
    Protein-truncating variants of the cholesteryl ester transfer protein gene and risk for coronary artery disease among patients with heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2025;408:120417.
    >> Share

    June 2025
  39. SHAO C, Zhang S, Cheng Z, Yang K, et al
    Efficacy and safety of ongericimab in Chinese statin-intolerant patients with primary hypercholesterolemia or mixed dyslipidemia: a randomized, placebo-controlled phase 3 trial.
    Atherosclerosis. 2025;407:120408.
    >> Share

  40. SCHUITEMA PCE, Visseren FLJ, Nordestgaard BG, Teraa M, et al
    Elevated triglycerides are related to higher residual cardiovascular disease and mortality risk independent of lipid targets and intensity of lipid-lowering therapy in patients with established cardiovascular disease.
    Atherosclerosis. 2025 Jun 14:120411. doi: 10.1016/j.atherosclerosis.2025.120411.
    >> Share

  41. GIJON-CONDE T, Banegas JR, Sanchez CF, Alonso R, et al
    Clinical profile of familial hypercholesterolemia phenotype in adults attended in primary care in a large healthcare area.
    Atherosclerosis. 2025 Jun 4:120400. doi: 10.1016/j.atherosclerosis.2025.120400.
    >> Share

    May 2025
  42. NIGMANN C, Neyer M, Draxler-Dworzak S, Baumgartner-Kaut M, et al
    Evinacumab and reduced lipoprotein apheresis in pediatric homozygous familial hypercholesterolemia: a retrospective study on LDL-C.
    Atherosclerosis. 2025;406:119234.
    >> Share

  43. KHOLAIF N, Batha L, Aljenedil S, Awan ZA, et al
    Homozygous familial hypercholesterolemia evaluation and survival single center study in Saudi Arabia: The HESSA registry.
    Atherosclerosis. 2025;405:119214.
    >> Share

  44. VAHDAT-LASEMI F, Farhoudi L, Hosseinikhah SM, Santos RD, et al
    Angiopoietin-like protein inhibitors: Promising agents for the treatment of familial hypercholesterolemia and atherogenic dyslipidemia.
    Atherosclerosis. 2025;405:119235.
    >> Share

    April 2025
  45. SANTOS RD, Ray KK, De Bacquer D, Jennings C, et al
    Frequency of residual combined dyslipidemia and hypertriglyceridemia in patients with coronary heart disease in 13 countries across 6 WHO Regions: Results from INTERASPIRE.
    Atherosclerosis. 2025;405:119215.
    >> Share

  46. BASHIR B, Pasha R, Kamath A, Malik RA, et al
    Small nerve fibre damage and cardiac autonomic dysfunction in patients with hypertriglyceridaemia.
    Atherosclerosis. 2025;405:119186.
    >> Share

  47. TADA H, Nohara A, Usui S, Sakata K, et al
    Impact of the clinical diagnostic strata of familial hypercholesterolemia on risk stratification among patients with hypercholesterolemia.
    Atherosclerosis. 2025;404:119185.
    >> Share

  48. MULDER JWCM, Schonck WAM, Tromp TR, Reijman MD, et al
    Real-world family planning and pregnancy practices in women with homozygous familial hypercholesterolemia.
    Atherosclerosis. 2025;404:119187.
    >> Share

  49. BRINTON EA, Eckel RH, Gaudet D, Ballantyne CM, et al
    Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA.
    Atherosclerosis. 2025;403:119114.
    >> Share

    March 2025
  50. STONEHOUSE W, Benassi-Evans B, Louise J
    The effects of a novel nutraceutical combination on low-density lipoprotein cholesterol and other markers of cardiometabolic health in adults with hypercholesterolaemia: A randomised double-blind placebo-controlled trial.
    Atherosclerosis. 2025;403:119177.
    >> Share

  51. MICHIKURA M, Ogura M, Hori M, Matsuki K, et al
    Association of Achilles tendon thickness with lipid profile and carotid IMT in patients with familial hypercholesterolemia.
    Atherosclerosis. 2025;403:119173.
    >> Share

  52. VAN DEN BOSCH SE, Hutten BA, Revers A, Schrauben EM, et al
    Association between statin adherence and arterial stiffness in young adult patients with familial hypercholesterolemia: A cross-sectional study.
    Atherosclerosis. 2025;404:119175.
    >> Share

    February 2025
  53. DANIELE T, Laura D, Miriam L, Diane B, et al
    The vicious circle of chronic kidney disease and hypertriglyceridemia: What is first, the hen or the egg?
    Atherosclerosis. 2025;403:119146.
    >> Share

  54. IYEN B, Qureshi N, Kai J, Capps N, et al
    Cardiovascular disease morbidity is associated with social deprivation in subjects with familial hypercholesterolaemia (FH): A retrospective cohort study of individuals with FH in UK primary care and the UK Simon Broome register, linked with national
    Atherosclerosis. 2025;403:119142.
    >> Share

  55. AIN Q, Sikonja J, Sadiq F, Shafi S, et al
    Cascade screening of a Pakistani consanguineous familial hypercholesterolemia cohort: Identification of seven new homozygous patients.
    Atherosclerosis. 2025;402:119118.
    >> Share

  56. PAVANELLO C, Suppressa P, Castiglione S, Di Costanzo A, et al
    Sex-related differences in response to lomitapide in HoFH: A subanalysis of the Pan-European Lomitapide retrospective observational study.
    Atherosclerosis. 2025;401:119089.
    >> Share

    January 2025
  57. LIN J, Ji Y, Wang G, Ma X, et al
    Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: A randomized, double-blind, placebo-controlled phase 3 trial.
    Atherosclerosis. 2025;403:119120.
    >> Share

  58. GROSELJ U, Kafol J, Molk N, Sedej K, et al
    Prevalence, genetic variants, and clinical implications of hypocholesterolemia in children.
    Atherosclerosis. 2025;400:119065.
    >> Share

    December 2024
  59. AZAR Y, Ludwig TE, Le Bon H, Strom TB, et al
    The singular French PCSK9-p.Ser127Arg gain-of-function variant: A significant player in cholesterol levels from a 775-year-old common ancestor.
    Atherosclerosis. 2024;399:118596.
    >> Share

  60. HEATON J, Alshami A, Imburgio S, Upadhyaya V, et al
    Comparison of pooled cohort equation and PREVENT risk calculator for statin treatment allocation.
    Atherosclerosis. 2024;399:118626.
    >> Share

    November 2024
  61. SCHETTLER VJJ, Selke N, Jenke S, Zimmermann T, et al
    The German Lipoprotein Apheresis Registry-Summary of the eleventh annual report.
    Atherosclerosis. 2024;398:118601.
    >> Share

    October 2024
  62. BENITEZ-AMARO A, Garcia E, La Chica Lhoest MT, Martinez A, et al
    Targeting LDL aggregation decreases atherosclerotic lipid burden in a humanized mouse model of familial hypercholesterolemia: Crucial role of ApoB100 conformational stabilization.
    Atherosclerosis. 2024 Oct 19:118630. doi: 10.1016/j.atherosclerosis.2024.118630.
    >> Share

  63. SMITH TKT, Ghorbani P, LeBlond ND, Nunes JRC, et al
    AMPK-mediated regulation of endogenous cholesterol synthesis does not affect atherosclerosis in a murine Pcsk9-AAV model.
    Atherosclerosis. 2024;397:117608.
    >> Share

    September 2024
  64. LLEWELLYN A, Simmonds M, Marshall D, Harden M, et al
    Efficacy and safety of statins, ezetimibe and statins-ezetimibe therapies for children and adolescents with heterozygous familial hypercholesterolaemia: Systematic review, pairwise and network meta-analyses of randomised controlled trials.
    Atherosclerosis. 2024 Sep 28:118598. doi: 10.1016/j.atherosclerosis.2024.118598.
    >> Share

  65. BEA AM, Gonzalez-Guerrero A, Cenarro A, Lamiquiz-Moneo I, et al
    Association of HDL cholesterol with all-cause and cardiovascular mortality in primary hypercholesterolemia.
    Atherosclerosis. 2024 Sep 26:118617. doi: 10.1016/j.atherosclerosis.2024.118617.
    >> Share

    August 2024
  66. STOYELL-CONTI FF, Suresh Kumar M, Zigmond ZM, Rojas MG, et al
    Gene inactivation of lysyl oxidase in smooth muscle cells reduces atherosclerosis burden and plaque calcification in hyperlipidemic mice.
    Atherosclerosis. 2024;397:118582.
    >> Share

  67. EYRICH TM, Dalila N, Christoffersen M, Tybjaerg-Hansen A, et al
    Polygenic risk of high LDL cholesterol and ischemic heart disease in the general population.
    Atherosclerosis. 2024;397:118574.
    >> Share

    June 2024
  68. TADA H, Takamura M
    Toward personalized medicine in patients with familial hypercholesterolemia.
    Atherosclerosis. 2024 Jun 18:118522. doi: 10.1016/j.atherosclerosis.2024.118522.
    >> Share

  69. IBRAHIM S, Hartgers ML, Reeskamp LF, Zuurbier L, et al
    LDLR variant classification for improved cardiovascular risk prediction in familial hypercholesterolemia.
    Atherosclerosis. 2024 Jun 10:117610. doi: 10.1016/j.atherosclerosis.2024.117610.
    >> Share

    May 2024
  70. BERBERICH AJ, Hegele RA
    Pancreatitis risk in genetic subtypes of multifactorial chylomicronemia syndrome.
    Atherosclerosis. 2024;392:117528.
    >> Share

    April 2024
  71. HARADA-SHIBA M
    How can we improve the prognosis of patients with homozygous familial hypercholesterolemia?
    Atherosclerosis. 2024 Apr 16:117551. doi: 10.1016/j.atherosclerosis.2024.117551.
    >> Share

  72. HENDY LE, Spees LP, Tak C, Carpenter DM, et al
    An evaluation of the cost-effectiveness of population genetic screening for familial hypercholesterolemia in US patients.
    Atherosclerosis. 2024;393:117541.
    >> Share

  73. IBRAHIM S, Nurmohamed NS, Nierman MC, de Goeij JN, et al
    Enhanced identification of familial hypercholesterolemia using central laboratory algorithms.
    Atherosclerosis. 2024;393:117548.
    >> Share

  74. BASHIR B, Kwok S, Wierzbicki AS, Jones A, et al
    Validation of the familial chylomicronaemia syndrome (FCS) score in an ethnically diverse cohort from UK FCS registry: Implications for diagnosis and differentiation from multifactorial chylomicronaemia syndrome (MCS).
    Atherosclerosis. 2024;391:117476.
    >> Share

    March 2024
  75. REIJMAN MD, Kusters DM, Groothoff JW, Arbeiter K, et al
    Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolaemia: An expert consensus statement from ERKNet and ESPN.
    Atherosclerosis. 2024;392:117525.
    >> Share

  76. ALONSO R, Arroyo-Olivares R, Diaz-Diaz JL, Fuentes-Jimenez F, et al
    Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study.
    Atherosclerosis. 2024 Mar 16:117516. doi: 10.1016/j.atherosclerosis.2024.117516.
    >> Share

  77. MELNES T, Bogsrud MP, Christensen JJ, Rundblad A, et al
    Gene expression profiling in elderly patients with familial hypercholesterolemia with and without coronary heart disease.
    Atherosclerosis. 2024;392:117507.
    >> Share

  78. ESCATE R, Padro T, Perez de Isla L, Fuentes F, et al
    Circulating miR-6821-5p levels and coronary calcification in asymptomatic familial hypercholesterolemia patients.
    Atherosclerosis. 2024;392:117502.
    >> Share

  79. SCHLEGEL A
    Diagnostic challenge of an APOB variant of uncertain significance resolved by transheterozygosity with a pathological LDLR variant and clinical response to therapy.
    Atherosclerosis. 2024;390:117460.
    >> Share

    February 2024
  80. GUAY SP, Paquette M, Taschereau A, Girard L, et al
    Acute pancreatitis risk in multifactorial chylomicronemia syndrome depends on the molecular cause of severe hypertriglyceridemia.
    Atherosclerosis. 2024 Feb 27:117489. doi: 10.1016/j.atherosclerosis.2024.117489.
    >> Share

    January 2024
  81. RAGGI P, Takyar FM, Gadiyaram V, Zhang C, et al
    Differential effect of atorvastatin and pravastatin on thoracic spine attenuation: A sub-analysis of a randomized clinical trial.
    Atherosclerosis. 2024;388:117425.
    >> Share

    December 2023
  82. WODAJE T, Mahdi A, Venkateshvaran A, Habel H, et al
    Higher prevalence of coronary microvascular dysfunction in asymptomatic individuals with high levels of lipoprotein(a) with and without heterozygous familial hypercholesterolaemia.
    Atherosclerosis. 2023;389:117439.
    >> Share

  83. ANDRADE MM, Neto Goncalves T, Cruz D
    Familial hypercholesterolemia diagnostic challenge: Is Artificial Intelligence the key?
    Atherosclerosis. 2023 Dec 27:117435. doi: 10.1016/j.atherosclerosis.2023.117435.
    >> Share

  84. FISHBEIN I, Inamdar VV, Alferiev IS, Bratinov G, et al
    Hypercholesterolemia exacerbates in-stent restenosis in rabbits: Studies of the mitigating effect of stent surface modification with a CD47-derived peptide.
    Atherosclerosis. 2023;390:117432.
    >> Share

    November 2023
  85. MOLOKHIA M, Wierzbicki AS, Williams H, Kirubakaran A, et al
    Assessment of ethnic inequalities in diagnostic coding of familial hypercholesterolaemia (FH): A cross-sectional database study in Lambeth, South London.
    Atherosclerosis. 2023;388:117353.
    >> Share

  86. ZUBIRAN R, Vargas-Vazquez A, Olvera FDR, Cruz-Bautista I, et al
    Performance of the enhanced Sampson-NIH equation for VLDL-C and LDL-C in a population with familial combined hyperlipidemia.
    Atherosclerosis. 2023;386:117364.
    >> Share

  87. HOLVEN KB, Roeters van Lennep J
    Sex differences in lipids: A life course approach.
    Atherosclerosis. 2023;384:117270.
    >> Share

  88. GOLDBERG AC, Banach M, Catapano AL, Duell PB, et al
    Evaluation of the efficacy and safety of bempedoic acid in women and men: Pooled analyses from phase 3 trials.
    Atherosclerosis. 2023;384:117192.
    >> Share

    October 2023
  89. KATZMANN JL, Laufs U
    Liver transplantation for homozygous familial hypercholesterolemia: Cure for a genetic disease?
    Atherosclerosis. 2023 Oct 16:117337. doi: 10.1016/j.atherosclerosis.2023.117337.
    >> Share

  90. JUNNA N, Ruotsalainen S, Ripatti P, FinnGen, et al
    Novel Finnish-enriched variants causing severe hypercholesterolemia and their clinical impact on coronary artery disease.
    Atherosclerosis. 2023 Oct 12:117327. doi: 10.1016/j.atherosclerosis.2023.117327.
    >> Share

  91. PAGE MM, Hardikar W, Alex G, Bates S, et al
    Long-term outcomes of liver transplantation for homozygous familial hypercholesterolaemia in Australia and New Zealand.
    Atherosclerosis. 2023 Oct 10:117305. doi: 10.1016/j.atherosclerosis.2023.117305.
    >> Share

  92. SANTOS RD
    Improving pediatric familial hypercholesterolemia diagnosis by looking deeper into families.
    Atherosclerosis. 2023 Oct 1:117317. doi: 10.1016/j.atherosclerosis.2023.117317.
    >> Share

    September 2023
  93. ALBUQUERQUE J, Medeiros AM, Alves AC, Jannes CE, et al
    Generation and validation of a classification model to diagnose familial hypercholesterolaemia in adults.
    Atherosclerosis. 2023;383:117314.
    >> Share

    August 2023
  94. CASULA M, Gazzotti M, Capra ME, Olmastroni E, et al
    Refinement of the diagnostic approach for the identification of children and adolescents affected by familial hypercholesterolemia: Evidence from the LIPIGEN study.
    Atherosclerosis. 2023 Aug 12:117231. doi: 10.1016/j.atherosclerosis.2023.117231.
    >> Share

  95. HON A, Hsu JJ, Zambrano A, Xia Y, et al
    Effects of activity levels on aortic calcification in hyperlipidemic mice as measured by microPETmicroCT.
    Atherosclerosis. 2023;380:117198.
    >> Share

  96. SHAPIRO MD, Taub PR, Louie MJ, Lei L, et al
    Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: Pooled analysis of data from four phase 3 clinical trials.
    Atherosclerosis. 2023;378:117182.
    >> Share

  97. MURPHY JM, Jeong K, Tran DTK, Cioffi DL, et al
    Nuclear FAK in endothelium: An intrinsic inhibitor of NF-kappaB activation in atherosclerosis.
    Atherosclerosis. 2023;379:117189.
    >> Share

    July 2023
  98. SIMONEN P, Oorni K, Sinisalo J, Strandberg TE, et al
    High cholesterol absorption: A risk factor of atherosclerotic cardiovascular diseases?
    Atherosclerosis. 2023;376:53-62.
    >> Share

    June 2023
  99. JONES A, Peers K, Wierzbicki AS, Ramachandran R, et al
    Long-term effects of volanesorsen on triglycerides and pancreatitis in patients with familial chylomicronaemia syndrome (FCS) in the UK Early Access to Medicines Scheme (EAMS).
    Atherosclerosis. 2023;375:67-74.
    >> Share

  100. COSIN-SALES J, Campuzano Ruiz R, Diaz Diaz JL, Escobar Cervantes C, et al
    Impact of physician's perception about LDL cholesterol control in clinical practice when treating patients in Spain.
    Atherosclerosis. 2023;375:38-44.
    >> Share

    May 2023
  101. DOI T, Langsted A, Nordestgaard BG
    Dual elevated remnant cholesterol and C-reactive protein in myocardial infarction, atherosclerotic cardiovascular disease, and mortality.
    Atherosclerosis. 2023 May 13:S0021-9150(23)00204.
    >> Share

  102. SONMEZ A, Demirci I, Haymana C, Tasci I, et al
    Clinical characteristics of adult and paediatric patients with familial hypercholesterolemia: A real-life cross-sectional study from the Turkish National Database.
    Atherosclerosis. 2023;375:9-20.
    >> Share

    April 2023
  103. RODRIGUEZ-BORJABAD C, Narveud I, Christensen JJ, Ibarretxe D, et al
    Association between Nordic and Mediterranean diets with lipoprotein phenotype assessed by (1)HNMR in children with familial hypercholesterolemia.
    Atherosclerosis. 2023;373:38-45.
    >> Share

  104. SCHREUDER MM, Hamkour S, Siegers KE, Holven KB, et al
    LDL cholesterol targets rarely achieved in familial hypercholesterolemia patients: A sex and gender-specific analysis.
    Atherosclerosis. 2023 Apr 13:S0021-9150(23)00139.
    >> Share

  105. HEDEGAARD BS, Bork CS, Kanstrup HL, Thomsen KK, et al
    Genetic testing increases the likelihood of a diagnosis of familial hypercholesterolaemia among people referred to lipid clinics: Danish national study.
    Atherosclerosis. 2023;373:10-16.
    >> Share

    March 2023
  106. TADA H, Nomura A, Nohara A, Usui S, et al
    Attainment of the low-density lipoprotein cholesterol treatment target and prognosis of heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2023 Mar 17:S0021-9150(23)00103.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016